Company Inspyr Therapeutics, Inc. Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 08-01-31 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 16-10-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 5,000 | 0 | 0 | 100.00 % |
Stock B | 0 | 5,000 | 0 | 0 | |
Stock C | 0 | 290 | 0 | 0 | |
Stock D | 0 | 71 | 0 | 0 | |
Stock E | 0 | 134 | 0 | 0 | |
Stock F | 1 | 32,132,907 | 32,132,903 ( 100.00 %) | 0 | |
Stock G | 0 | 8,000 | 0 | 0 |
Company contact information
Rebus Holdings, Inc.
2629 Townsgate Road Suite 215
91361, Westlake Village
+818-661-6302
http://www.inspyrtherapeutics.com![address Inspyr Therapeutics, Inc.(NSPX)](https://cdn.zonebourse.com/static/address/66771991.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.12% | 127B | |
+25.25% | 117B | |
+25.56% | 27.77B | |
-19.51% | 20.44B | |
-14.36% | 16.62B | |
-15.63% | 15.92B | |
-46.67% | 14.94B | |
+11.89% | 14.74B | |
+57.74% | 14.38B |